Like many of you, we saw the Jan. 26 announcement from the FDA, which stated that “… the agency has concluded that existing regulatory frameworks for food and supplements are not appropriate and the agency will work with Congress on a new way forward.” Also in the announcement was a statement that, “In addition, a new pathway could provide access and oversight for certain CBD-containing products for animals,” which is very consistent with our discussions with our contacts at FDA-CVM.
On behalf of our members, NASC has been on the forefront of this issue since 2015. Following our testimony at FDA’s Public Meeting in 2019, we provided the agency with our program for what we believe are components of a responsible path forward. Our program includes virtually all general requirements mentioned in the announcement, and in addition, we are in the final stages of completing our long-term safety study for CBD, CBD/CBA and CBD/CBG in dogs. The results of our study have shown very favorable results within the administration ranges we identified.
Over our 21-year history, we have always worked very successfully with the FDA to define, develop, and implement regulatory pathways that provide responsible outcomes for all stakeholders while maintaining regulatory oversight. We view this announcement and indications we have received from FDA-CVM as positive progress, and we welcome the opportunity to continue to help shape a viable path forward.
Doing the right things right ALWAYS pays dividends in the long run.
Sincerely,
—Bill Bookout, NASC President
